CalciMedica (CALC) Competitors

$0.68 0.00 (0.00%)

As of 03:14 PM Eastern

CALC vs. ATNM, MREO, NXTC, ATHA, and EVAX

Should you buy CalciMedica stock or one of its competitors? MarketBeat compares CalciMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CalciMedica include Actinium Pharmaceuticals (ATNM), Mereo BioPharma Group (MREO), NextCure (NXTC), Athira Pharma (ATHA), and Evaxion A/S (EVAX). These companies are all part of the "pharmaceutical products" industry.

How does CalciMedica compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 41.6% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Actinium Pharmaceuticals currently has a consensus target price of $4.50, indicating a potential upside of 254.33%. CalciMedica has a consensus target price of $10.00, indicating a potential upside of 1,366.28%. Given CalciMedica's higher probable upside, analysts plainly believe CalciMedica is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Actinium Pharmaceuticals' return on equity of -100.85% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
CalciMedica	N/A	-1,093.51%	-144.33%

CalciMedica has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	442.74	-$48.82M	-$0.75	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

Actinium Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

In the previous week, CalciMedica had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 6 mentions for CalciMedica and 5 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.00 beat CalciMedica's score of 0.98 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Positive
CalciMedica	Positive

Summary

Actinium Pharmaceuticals beats CalciMedica on 8 of the 14 factors compared between the two stocks.

How does CalciMedica compare to Mereo BioPharma Group?

CalciMedica (NASDAQ:CALC) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

CalciMedica currently has a consensus target price of $10.00, suggesting a potential upside of 1,366.28%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 1,277.12%. Given CalciMedica's higher possible upside, equities analysts plainly believe CalciMedica is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

62.8% of Mereo BioPharma Group shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Mereo BioPharma Group had 2 more articles in the media than CalciMedica. MarketBeat recorded 8 mentions for Mereo BioPharma Group and 6 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.98 beat Mereo BioPharma Group's score of -0.39 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

CalciMedica has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Mereo BioPharma Group	$500K	75.34	-$41.88M	-$0.05	N/A

Mereo BioPharma Group's return on equity of -81.28% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-1,093.51%	-144.33%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Summary

Mereo BioPharma Group beats CalciMedica on 8 of the 14 factors compared between the two stocks.

How does CalciMedica compare to NextCure?

CalciMedica (NASDAQ:CALC) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

42.7% of NextCure shares are held by institutional investors. 41.6% of CalciMedica shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NextCure's return on equity of -186.96% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-1,093.51%	-144.33%
NextCure	N/A	-186.96%	-124.62%

CalciMedica presently has a consensus price target of $10.00, suggesting a potential upside of 1,366.28%. NextCure has a consensus price target of $23.00, suggesting a potential upside of 137.97%. Given CalciMedica's higher possible upside, analysts clearly believe CalciMedica is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, CalciMedica had 2 more articles in the media than NextCure. MarketBeat recorded 6 mentions for CalciMedica and 4 mentions for NextCure. CalciMedica's average media sentiment score of 0.98 beat NextCure's score of 0.11 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NextCure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, NextCure has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

NextCure is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Summary

CalciMedica beats NextCure on 7 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Athira Pharma presently has a consensus target price of $4.00, suggesting a potential downside of 63.64%. CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,366.28%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts clearly believe CalciMedica is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Athira Pharma is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

Athira Pharma's return on equity of -107.06% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
CalciMedica	N/A	-1,093.51%	-144.33%

57.1% of Athira Pharma shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CalciMedica had 6 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for CalciMedica and 0 mentions for Athira Pharma. CalciMedica's average media sentiment score of 0.98 beat Athira Pharma's score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
CalciMedica	Positive

Summary

CalciMedica beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Evaxion A/S's return on equity of -73.56% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
CalciMedica	N/A	-1,093.51%	-144.33%

In the previous week, CalciMedica had 4 more articles in the media than Evaxion A/S. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for Evaxion A/S. CalciMedica's average media sentiment score of 0.98 beat Evaxion A/S's score of 0.94 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evaxion A/S has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Evaxion A/S has higher revenue and earnings than CalciMedica. Evaxion A/S is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.41	-$7.71M	-$1.47	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

11.0% of Evaxion A/S shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 176.38%. CalciMedica has a consensus target price of $10.00, indicating a potential upside of 1,366.28%. Given CalciMedica's higher possible upside, analysts clearly believe CalciMedica is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Evaxion A/S beats CalciMedica on 8 of the 14 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.79M	$3.31B	$6.23B	$12.35B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.52	18.15	20.41	25.39
Price / Sales	N/A	281.36	541.58	73.15
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	-9.74	6.74	9.83	6.93
Net Income	-$29.56M	$24.11M	$3.56B	$333.88M
7 Day Performance	8.43%	3.92%	0.52%	0.03%
1 Month Performance	7.38%	-2.85%	-0.71%	1.93%
1 Year Performance	-64.85%	68.91%	36.34%	33.14%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	2.8356 of 5 stars	$0.68 flat	$10.00 +1,370.6%	-64.5%	$10.76M	N/A	N/A	30	Short Interest Decrease
ATNM Actinium Pharmaceuticals	3.2383 of 5 stars	$1.25 -0.8%	$4.50 +260.0%	-12.3%	$39.22M	$90K	N/A	30	Positive News Analyst Revision
MREO Mereo BioPharma Group	3.1563 of 5 stars	$0.24 -12.5%	$3.25 +1,232.0%	-89.4%	$38.95M	$500K	N/A	40	News Coverage Earnings Report Analyst Forecast Gap Up
NXTC NextCure	2.2466 of 5 stars	$10.53 +12.9%	$23.00 +118.5%	+92.1%	$38.00M	N/A	N/A	90	Gap Down
ATHA Athira Pharma	N/A	$9.63 +0.8%	$4.00 -58.5%	+297.4%	$37.98M	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. ATNM, MREO, NXTC, ATHA, and EVAX

How does CalciMedica compare to Actinium Pharmaceuticals?

Summary

How does CalciMedica compare to Mereo BioPharma Group?

Summary

How does CalciMedica compare to NextCure?

Summary

How does CalciMedica compare to Athira Pharma?

Summary

How does CalciMedica compare to Evaxion A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. ATNM, MREO, NXTC, ATHA, and EVAX

How does CalciMedica compare to Actinium Pharmaceuticals?

Do institutionals & insiders believe in ATNM or CALC?

Do analysts prefer ATNM or CALC?

Is ATNM or CALC more profitable?

Which has higher earnings & valuation, ATNM or CALC?

Which has more volatility & risk, ATNM or CALC?

Does the media favor ATNM or CALC?

Summary

How does CalciMedica compare to Mereo BioPharma Group?

Do analysts rate CALC or MREO?

Do institutionals & insiders hold more shares of CALC or MREO?

Does the media refer more to CALC or MREO?

Which has more risk & volatility, CALC or MREO?

Which has better valuation & earnings, CALC or MREO?

Is CALC or MREO more profitable?

Summary

How does CalciMedica compare to NextCure?

Do institutionals & insiders have more ownership in CALC or NXTC?

Is CALC or NXTC more profitable?

Do analysts recommend CALC or NXTC?

Does the media favor CALC or NXTC?

Which has more risk & volatility, CALC or NXTC?

Which has preferable earnings and valuation, CALC or NXTC?

Summary

How does CalciMedica compare to Athira Pharma?

Which has more risk and volatility, ATHA or CALC?

Do analysts rate ATHA or CALC?

Which has stronger earnings & valuation, ATHA or CALC?

Is ATHA or CALC more profitable?

Do insiders & institutionals hold more shares of ATHA or CALC?

Does the media favor ATHA or CALC?

Summary

How does CalciMedica compare to Evaxion A/S?

Is EVAX or CALC more profitable?

Does the media favor EVAX or CALC?

Which has more risk and volatility, EVAX or CALC?

Which has better valuation and earnings, EVAX or CALC?

Do institutionals and insiders believe in EVAX or CALC?

Do analysts recommend EVAX or CALC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools